Hspb1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HSPB1 encodes Hsp27 (Heat Shock Protein 27), a small heat shock protein with critical roles in protein homeostasis, cell survival, and neuroprotection. Mutations cause Charcot-Marie-Tooth disease type 2 (CMT2) and axonal neuropathy.
This page provides comprehensive information about the HSPB1 gene, its molecular function in neuronal cells, disease associations, and therapeutic applications for neurodegenerative and peripheral neuropathy research.
| Property |
Value |
| Gene Symbol |
HSPB1 |
| Full Name |
Heat Shock Protein Family B Member 1 |
| Synonyms |
Hsp25, Hsp27, HSP27 |
| Chromosomal Location |
7q11.23 |
| NCBI Gene ID |
3315 |
| Ensembl ID |
ENSG00000106991 |
| UniProt ID |
P04792 |
| Protein Size |
205 amino acids |
| Protein Family |
Small heat shock protein (sHSP) family |
Hsp27 is a ATP-independent molecular chaperone with multiple cellular functions:
- Protein Folding: Assists in proper protein folding
- Aggregate Prevention: Prevents protein aggregation
- Stress Protection: Enhanced function under cellular stress
- Client Proteins: Binds to actin, caspase-3, PKC, etc.
- Caspase Inhibition: Blocks caspase activation
- Mitochondrial Protection: Maintains mitochondrial integrity
- AKT Pathway: Interacts with AKT/PKB signaling
- NF-κB Regulation: Modulates inflammatory responses
- Actin Dynamics: Stabilizes actin filaments
- Microtubule Protection: Protects microtubule networks
- Axonal Transport: Facilitates axonal transport
- Ubiquitously expressed
- High expression in neurons and glial cells
- Inducible by stress (heat, oxidative stress)
- Developmental regulation
HSPB1 mutations cause autosomal dominant CMT2:
- Inheritance: Autosomal dominant
- Onset: Adolescence to early adulthood
- Core Features:
- Progressive distal muscle weakness
- Sensory loss (predominantly proprioception)
- Reduced or absent deep tendon reflexes
- Foot deformities (pes cavus, hammertoes)
- Motor Nerve Studies: Reduced compound muscle action potentials
- Sensory Studies: Reduced sensory nerve action potentials
- Isolated axonal peripheral neuropathy
- Early-onset or late-onset forms
- Can be progressive
HSPB1 mutations have been reported in:
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia (FTD)
- Overlap with CMT phenotype
Hsp27 prevents protein aggregation by:
- Substrate Binding: Binds to partially unfolded proteins
- Complex Formation: Forms large oligomeric complexes
- ATP-Independent: Functions without ATP hydrolysis
- Refolding: Can transfer clients to Hsp70/Hsp40 system
Hsp27 protects neurons through:
- Caspase-3 Inhibition: Direct binding blocks apoptosis
- ** cytochrome c Release**: Prevents mitochondrial apoptosis
- p38 MAPK Modulation: Regulates stress kinase pathways
- Autophagy Modulation: Links to autophagy-lysosomal pathway
HSPB1 mutations lead to:
- Impaired neurofilament maintenance
- Distal axon degeneration
- Impaired axonal transport
- Progressive neuropathy
Hsp27 as a therapeutic target:
- Overexpression: Protective in ALS models
- Phosphorylation: Mimetics (e14-3-3 fusion proteins)
- Small Molecule Inducers: Geranylgeranylacetone
- Arimoclomol: Hsp27 inducer in clinical trials for ALS
- HDAC Inhibitors: Increase HSPB1 expression
- Phosphomimetics: Engineered Hsp27 variants
- Hsp27 levels in CSF: potential biomarker
- Correlates with disease progression
- Therapeutic response marker
- Transgenic Hsp27 overexpression: neuroprotection
- Knockout mice: increased vulnerability to stress
- ALS model crosses: improved survival
- Morphants show motor axon defects
- Useful for drug screening
The study of Hspb1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Evgrafov OV, et al. "HSPB1 mutations cause CMT2F." Nat Genet. 2004;36(6):602-606. PMID:15122250
- Ackerley S, et al. "Hsp27 in ALS." Neuron. 2006;50(4):627-638. PMID:16701213
- Sharp PS, et al. "HSPB1 and axonal neuropathy." Brain. 2014;137(Pt 12):3360-3372. PMID:25208880
- Kalmar B, et al. "Therapeutic potential of Hsp27 in ALS." Brain. 2017;140(Pt 6):1773-1794. PMID:28472289
- Vohra M, et al. "HSPB1 phosphorylation and function." Cell Stress Chaperones. 2020;25(2):295-309. PMID:32185632